Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 101–150 of 18616
On August 3, 2026, David Miller notified Goldman Sachs Private Middle Market Credit II LLC (the “Company”) of his intention to resign as Co-Chief Executive Officer and co-principal executive officer of the Company.
Vivek Bantwal, the Company’s other co-Chief Executive Officer and co-principal executive officer, will, as of December 31, 2026, become the Company’s sole Chief Executive Officer and sole principal executive officer.
Vivek Bantwal, the Company’s other co-Chief Executive Officer and co-principal executive officer, will, as of December 31, 2026, become the Company’s sole Chief Executive Officer and sole principal executive officer.
On August 3, 2026, David Miller notified Silver Capital Holdings LLC (the “Company”) of his intention to resign as Co-Chief Executive Officer and co-principal executive officer of the Company.
On August 4, 2026, STAAR Surgical Company (the “Company” or “STAAR”) announced that the Company’s Board of Directors (the “Board”) appointed Warren Foust as President and Chief Executive Officer (“CEO”) and new member of the Board, effective August 4, 2026 (the “Effective Date”).
appointed Mr. Morrison as Chief Executive Officer effective upon approval of the Meeting Proposals.
Effective January 1, 2027, Scott Schaefer, the Company’s Senior Vice President, Finance and Transformation, will succeed Mr. DeSimone as the Company’s Chief Financial Officer (the “Transition”).
On July 30, 2026, John DeSimone, the Company’s Chief Financial Officer, notified the Board of Directors of the Company (the “Board”) of his intention to retire, effective December 31, 2026.
Jon S. Cummings IV was appointed as Chief Executive Officer, Treasurer and Secretary, and Sole Director of the Company.
Bruce Harmon was promoted from Controller to Chief Financial Officer of the Company
Robert Scannell resigned as Chief Financial Officer of Idaho Copper Corporation
On August 3, 2026, Albert J. Miralles, Chief Financial Officer and Executive Vice President, Enterprise Business Operations, informed CDW Corporation (the “Company”) of his intention to retire in 2027 following the completion of an orderly transition.
On July 30, 2026, the Board of Directors of the Company elected Daniel C. Kleine, the Company's Senior Vice President of Finance and Treasurer, to serve as Chief Financial Officer of the Company, effective immediately.
On August 4, 2026, Martin Marietta Materials, Inc. (the “Company”) announced that the Company has promoted Michael J. Petro to Executive Vice President, Chief Financial Officer.
On August 3, 2026, Georgia Electric Membership Corporation’s board of directors selected Heather H. Teilhet, our current Executive Vice President, External Affairs, as its next President/CEO, effective January 4, 2027.
Richard A. Poinsatte, the Company’s Executive Vice President and Treasurer, will become the Company’s Executive Vice President and Chief Financial Officer
Theresa E. Wagler, the Company’s Executive Vice President and Chief Financial Officer, will become the Company’s President and Chief Executive Officer
Effective July 31, 2026, the Board appointed Roman Franklin, age 42, as the Company’s Chief Financial Officer, and designated Mr. Franklin as the Company’s principal financial officer for purposes of the Securities Exchange Act of 1934, as amended.
On July 31, 2026, Bradford Amman resigned as Chief Financial Officer and Secretary of the Company, and from all other officer and committee positions held by reason of his employment, effective as of that date.
Angel Yik as Director and Secretary, as Chief Financial Officer (CFO)
Cheng Chung Yu (Neptune (HK)) as Director and Chief Executive Officer CEO
On August 3, 2026, Cue Biopharma, Inc. (the “Company”) announced that the Company’s Board of Directors (the “Board”) appointed James Ahlers as the Company’s Chief Financial Officer, effective as of July 30, 2026 (the “Effective Date”).
the Board of Directors of the Company (the “Board”) has appointed Julie Sawyer Montgomery as President and Chief Executive Officer of the Company (the “CEO”).
On July 28, 2026, the Board took action to expand Mr. Jackson’s responsibilities and, commensurate with such expansion, to also appoint Mr. Jackson as President of the Company, effective August 1, 2026, and to approve Mr. Jackson’s compensation arrangements for his role as President and CEO, in each case effective August 1, 2026.
the Company announced that effective January 1, 2027 (“the Effective Date”), Cory S. Gunderson will succeed Mr. Tarantino and serve as President and Chief Executive Officer - Protiviti.
Joseph A. Tarantino has informed the Board of Directors that effective December 31, 2026 he will transition from his position as President and Chief Executive Officer – Protiviti to a new position as Senior Managing Director, Protiviti commencing January 1, 2027.
Simultaneously, the following individual was elected: Stephen Ken Adair as its President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Director.
Effective August 3, 2026, the Company accepted the resignation of Alexander M. Woods-Leo from all of his positions with the Company, including President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, and Director.
On July 31, 2026, the Board appointed Joel Krutz, the Company’s Chief Financial Officer, to serve as interim Chief Executive Officer of the Company, effective immediately, while the Board conducts a search for a permanent successor.
On July 31, 2026, the Board of Directors (the “Board”) of Amaze Holdings, Inc. (the “Company”) determined that Aaron Day would no longer serve as Chief Executive Officer of the Company, effective immediately.
On July 28, 2026, Research Solutions, Inc. (the “Company”) appointed Dave Kutil as the Company’s Chief Financial Officer (“CFO”).
John Militello, CPA , age 52, was conditionally appointed as the Company’s Chief Financial Officer
Brigette Roberts, M.D. , age 50, was conditionally appointed as the Company’s Chief Executive Officer
each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “ Company ”), and a member of the Company’s board of directors (the “ Board ”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company
Michelle Cervantes Vivanco as the Company’s Chief Financial Officer
Following Ms. Martin-Garcia's appointment, Mr. Kraus will return to his role as the Company's Chief Financial Officer and principal financial officer.
On July 29, 2026, the Board of Directors elected Erica McLaughlin President and Chief Executive Officer of the Company, effective October 1, 2026.
On July 24, 2026, Sean D. Keohane of Cabot Corporation (the “Company”) notified the Company’s Board of Directors (the “Board”) of his decision to retire as President and Chief Executive Officer and resign as a Director of the Company and a member of the Board’s Executive Committee, each effective September 30, 2026.
On July 24, 2026, the Board of Directors of Olenox Industries, Inc. (the “Company”) appointed Kimberly Hawley as the Company’s Interim Chief Financial Officer
the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer
each of David Domzalski, VYNE’s President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE’s Chief Scientific Officer, and Mutya Harsch, VYNE’s Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026
the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer
on July 22, 2026, Mr. Dunn notified the Company that his resignation as CFO will be effective August 21, 2026
On July 22, 2026, TransparentBusiness, Inc., (the “Company”) received notice that Andrew Winn resigned from his position as Chief Financial Officer, effective August 4, 2026, due to personal reasons.
On July 26, 2026, the Board of Directors of ZipRecruiter, Inc. (the “Company”), approved the appointment of Carmen Chan, age 40, as the Company’s Chief Financial Officer and principal financial officer, with such appointment to be effective as of August 17, 2026.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
David Deno, will assume the role of President and Chief Executive Officer
Julie Masino, the Company’s President and Chief Executive Officer, will step down from that role effective August 10, 2026
On July 23, 2026, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) appointed Michael Severino, M.D. as Chief Executive Officer of the Company, effective July 28, 2026
Mr. Ingram will depart from his position as Chief Executive Officer and a member of the Board as of the Effective Date.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.